Carpentier-Edwards PERIMOUNT Theon RSR Pericardial Aortic Bioprosthesis with ThermaFix tissue process; Carpentier-Edwar
Edwards Lifesciences, LLC · Decision date Mar 11, 2026
What did the FDA decide?
FDA records P860057/S224 as a supplement to PMA P860057, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 11, 2026.
FDA approval order statement
alternate suppliers of solutions used in the manufacturing process of transcatheter and surgical heart valves
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P860057/S224
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- DYE
- Decision code
- OK30
- Decision date
- Mar 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: replacement Heart-valve.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- DYE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P860057. Subsequent supplements may change the device or its indications.
FDA decision timeline
P860057 · Original PMA
EDWARDS LIFESCIENCES PERIMOUNT AORTIC AND MITRAL BIOPROSTHESES
P860057/S223 · Related supplement
Carpentier-Edwards PERIMOUNT RSR Pericardial Aortic Bioprosthesis; Carpentier-Edwards PERIMOUNT Plus Mitral Bioprosthesi
P860057/S224 received
Application receipt date recorded by FDA.
P860057/S224 · FDA decision
30-Day Notice
P860057/S225 · Related supplement
Carpentier-Edwards PERIMOUNT Magna Ease Aortic Heart Valve, Carpentier-Edwards PERIMOUNT Magna Mitral Ease Bioprosthesis
P860057/S226 · Related supplement
Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Aortic Bioprosthesis
P860057/S227 · Related supplement
Carpentier-Edwards PERIMOUNT RSR Pericardial Aortic Bioprosthesis Model 2800; Carpentier-Edwards PERIMOUNT RSR Pericardi
P860057/S228 · Related supplement
Carpentier-Edwards PERIMOUNT Theon RSR Pericardial Aortic Bioprosthesis with ThermaFix tissue process (2800TFX), Carpen
Timeline entries are records held by MedtechLedger for P860057. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P860057
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Sep 26, 1991 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 16, 2025 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Apr 16, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Jun 3, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
Explore the linked device profile
Other records with product code DYE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Mosaic Neo Mitral BioprosthesisP990064/S094 | Medtronic, Inc. | PMA supplement | Mar 3, 2026 | FDA |
Hancock II BioprosthesisP980043/S086 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
Mosaic BioprosthesisP990064/S096 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
Hancock II BioprosthesisP980043/S084 | Medtronic, Inc. | PMA supplement | Nov 10, 2025 | FDA |
Mosaic BioprosthesisP990064/S093 | Medtronic, Inc. | PMA supplement | Nov 10, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P860057/S224
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





